TORONTO, October 7, 2025 — Leads & Copy — Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) today announced preliminary unaudited revenues for the third quarter of 2025, anticipating total revenues to be in the approximate range of $5.2 million to $5.3 million, representing revenue growth of between 84% and 87% over $2.8 million in the same three-month period a year ago. Gross margin is expected to be approximately 72% for the third quarter of 2025, compared to 64% in the prior year period. All amounts in this press release are expressed in U.S. dollars unless specified otherwise.
Profound’s CEO and Chairman, Arun Menawat, noted that the company achieved new highs in terms of both TULSA-PRO® installed base growth and existing system utilization, driving record total revenues during the third quarter. The TULSA-PRO installed base now sits at 67, up from 60, and the company continues to expect to reach at least 75 by the end of the year due to a strong and growing capital sales pipeline.
The company plans to announce its full third quarter 2025 financial results after market close on Thursday, November 13, 2025. Profound management will host a conference call at 4:30 p.m. ET to review the financial results and discuss business developments in the period.
The live call registration is available at: https://register-conf.media-server.com/register/BI1d4819ae421e47ff95ddb48cba2afcea. The call will also be broadcast live and archived on the Company’s website under “News & Events” in the Investors section.
Profound Medical Corp. is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue. Profound is commercializing TULSA-PRO®, a technology that combines real-time MRI, AI-enhanced planning, robotically-driven transurethral ultrasound and closed-loop temperature feedback control.
Stephen Kilmer
Investor Relations
skilmer@profoundmedical.com
T: 647.872.4849
Source: Profound Medical Corp.
